Delivery Order SPE2DB25D3012-SPE2DB25FXABA
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of 1,000 units of Tamsulosin HCL 0.4 mg capsules, valued at $2,702.16. This contract represents a firm fixed-price delivery order with an ultimate completion date of August 26, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation, reflecting the contractor's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of 1,000 units of Tamsulosin HCL 0.4 mg capsules, with a contract ceiling value of $1,727.65. This is a firm fixed-price delivery order with no set-aside designation, performed at the contractor's corporate office location in Conshohocken, Pennsylvania, and scheduled for completion by August 8, 2025. The award represents a routine pharmaceutical supply transaction supporting...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 1,000 capsules of Tamsulosin HCL 0.4 mg, with a contract value of $13,611.53. The award was made on July 22, 2025, with an ultimate completion date of July 23, 2025, under a firm fixed-price delivery order with no set-aside designation. Performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- AmerisourceBergen Drug Corp was awarded a delivery order contract by the Defense Logistics Agency (DLA) on September 9, 2025, for the supply of Tamsulosin HCl 0.4 mg capsules in a quantity of 1,000 units, with a firm fixed price of $3,738.58 and an ultimate completion date of September 10, 2025. This non-set-aside, competitively awarded delivery order represents a continuation of AmerisourceBergen's pharmaceutical supply services to federal healthcare systems and will be performed at the...
- The Defense Logistics Agency awarded a $7,776.80 delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of 1,000 units of Tamsulosin HCL 0.4 mg capsules. This competitively awarded, non-set-aside contract carries a firm fixed price structure with an ultimate completion date of July 23, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The contract represents a continuation of AmerisourceBergen's ongoing pharmaceutical...
- The Defense Logistics Agency awarded a $9,621.08 delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of 1,000 units of Tamsulosin HCL 0.4 mg capsules. This contract is structured as a firm fixed price delivery order with an ultimate completion date of September 17, 2025, and represents a non-set-aside competitive award. The pharmaceutical will be supplied from the vendor's facility in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of 1,000 capsules of Tamsulosin HCL 0.4 mg, a common medication used to treat benign prostatic hyperplasia. This firm fixed-price delivery order, valued at $11,771.03, is scheduled for completion by August 14, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award was made through competitive procedures with no...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of 1,000 units of Tamsulosin HCL 0.4 mg capsules under a firm fixed price contract valued at $2,008.55. The delivery order was competitively awarded without a set-aside designation and is scheduled for completion by August 6, 2025. The product will be delivered to the contractor's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $3,738.42 on August 5, 2025, for the supply of Tamsulosin HCL 0.4 mg capsules (1,000 count). This award is non-competitive and carries a firm fixed price structure with completion targeted for August 6, 2025. The order will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. This delivery order is issued under a larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of 1,000 capsules of Tamsulosin HCL 0.4 mg, with a contract value of $1,192.79 and a completion date of September 2, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The pharmaceutical will be supplied from the vendor's location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen...
- SPE2DB25D3012Indefinite Delivery Contract
- SPE2DB25D3012-SPE2DB25FXABADelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of 1,000 units of Tamsulosin HCL 0.4 mg capsules, valued at $24,188.72. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The order is scheduled for completion by September 16, 2025, and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, is a critical vendor for federal medical procurement supporting military and veteran healthcare systems. The company's portfolio under its DLA contract encompasses a broad range of pharmaceutical products including specialty medications, brand-name and generic drugs, vaccines, and medical supplies across multiple therapeutic domains. Tamsulosin HCL, a common medication for urinary symptoms, represents one of the routine pharmaceutical commodities supplied through this vehicle to support Defense Health Agency and other government healthcare system requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $24.2k | 9/15/25 |